- BioCentriq, a cell therapy Contract Development and Manufacturing Organisation (CDMO), has significantly enhanced its partnership with Pluristyx Inc.
- This partnership aims to accelerate the development and commercialisation of iPSC-derived treatments.
BioCentriq, a cell therapy Contract Development and Manufacturing Organisation (CDMO), has announced a significant enhancement to its partnership with Pluristyx Inc., an early-stage biotechnology company specialising in Induced Pluripotent Stem Cell (iPSC) products.
Pluristyx’s unique clinical-grade iPSC lines, derived from regulatory-compliant starting material and reprogrammed using proprietary mRNA technology, represent a breakthrough in cell therapy development. These lines provide stability, scalability, and customisation potential for enhanced therapeutic outcomes.
“Expanding our collaboration with Pluristyx to include access to iPSC lines is a significant leap forward for BioCentriq and our clients,” said Alex Klarer, Vice President of Business Strategy and Innovation at BioCentriq. “This capability enhancement underscores BioCentriq’s commitment to providing our clients with state-of-the-art resources to accelerate the development and manufacture of innovative cell-based therapies including next-generation iPSC-derived treatments.”
“Pluristyx is excited to expand our relationship with BioCentriq to provide streamlined access to our research- and clinical-grade iPSC lines and accelerate the development of next generation therapeutics,” stated Dr Benjamin Fryer, Chief Executive Officer and Co-Founder of Pluristyx. “Our best-in-class iPSC lines offer a simplified path to commercialisation, and are made available pre-edited with our exclusive FailSafe™ and iACT Stealth Cells® platform technologies to provide unparalleled safety and cloaking capabilities to overcome the inherent challenges of iPSC-derived therapies.”
Overview of outsourcing trends 
